Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Crossref DOI link: https://doi.org/10.1007/s40123-023-00788-9
Published Online: 2023-08-11
Published Print: 2023-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yanagi, Yasuo
Takahashi, Kanji
Iida, Tomohiro
Gomi, Fumi
Morii, Junko
Kunikane, Eriko
Sakamoto, Taiji
Text and Data Mining valid from 2023-08-11
Version of Record valid from 2023-08-11
Article History
First Online: 11 August 2023